Risk factors for relapse in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: Tools for treatment decisions?

Clinical and Experimental Rheumatology

Volumn 22, Issue 6 SUPPL., 2004, Pages

  Sanders, J S R ^a   Stassen, P M ^a   Van Rossum, A P ^a   Kallenberg, C G M ^a   Stegeman, C A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ANCA associated vasculitis; Churg Strauss syndrome; Microscopic polyangiitis; Prevention; Relapses; Wegener's granulomatosis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; AZATHIOPRINE; METHOTREXATE; PREDNISOLONE;

ANCA ASSOCIATED VASCULITIS; FOLLOW UP; HEREDITY; HUMAN; LONG TERM CARE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RELAPSE; REVIEW; RISK FACTOR; T LYMPHOCYTE ACTIVATION; TREATMENT PLANNING; CELL ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC POLYMORPHISM; LEUKOCYTE ACTIVATION; NONHUMAN; PROTEIN EXPRESSION; RECURRENCE RISK; SINGLE NUCLEOTIDE POLYMORPHISM; STAPHYLOCOCCUS AUREUS; WEGENER GRANULOMATOSIS; BLOOD; DISEASE FREE SURVIVAL; GLOMERULONEPHRITIS; IMMUNOLOGY; PATHOLOGY; RECURRENT DISEASE; SURVIVAL RATE; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; DISEASE-FREE SURVIVAL; GLOMERULONEPHRITIS; HUMANS; RECURRENCE; RISK FACTORS; SURVIVAL RATE; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 15044355295     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. KALLENBERG CG, BROUWER E, WEENING JJ, COHEN TERVAERT JW: Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994; 46: 1-15.
2. FAUCI AS, WOLFF SM: Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) 1973; 52: 535-61.
3. HOFFMAN GS, KERR GS, LEAVITT RY et al.: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
4. JAYNE D, RASMUSSEN N, ANDRASSY K et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
5. REINHOLD-KELLER E, BEUGE N, LATZA U et al.: An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-32.
6. GORDON M, LUQMANI RA, ADU D et al.: Relapses in patients with a systemic vasculitis. Q J Med 1993; 86: 779-89.
7. KOLDINGSNES w, NOSSENT H: Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41:572-81.
8. SLOT MC, COHEN TERVAERT JW, FRANSSEN CF, STEGEMAN CA: Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003; 63: 670-7.
9. DE GROOT K, ADU D, SAVAGE CO: The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16: 2018-27.
10. KOLDINGSNES W, NOSSENT JC: Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol 2003; 30: 80-8.
11. REINHOLD-KELLER E, FINK CO, HERLYN K, GROSS WL, DE GROOT K: High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002; 47: 326-32.
12. DE GROOT K, RASMUSSEN N, BACON PA et al.: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in "non-renal" ANCA-associated vasculitis. Arthritis Rheum 2003; 48: S660.
13. SANDERS JS, SLOT MC, STEGEMAN CA: Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 2072-3.
14. NACHMAN PH, HOGAN SL, JENNETTE JC, FALK RJ: Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 33-9.
15. GUILLEVIN L, DURAND-GASSELIN B, CEVALLOS R et al.: Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42(3): 421-30.
16. JAYNE DR, GASKIN G, PUSEY CD, LOCKWOOD CM: ANCA and predicting relapse in systemic vasculitis. QJM 1995; 88: 127-33.
17. GASKIN G, SAVAGE CO, RYAN JJ et al.: Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991; 6: 689-94.
18. PETTERSSON E, HEIGL Z: Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study. Clin Nephrol 1992; 37: 219-28.
19. KYNDT X, REUMAUX D, BRIDOUX F et al.: Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999; 106: 527-33.
20. SLOT MC, COHEN TERVAERT JW, BOOMSMA MM, STEGEMAN CA: Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004; 51: 269-73.
21. REYNOLDS WF, STEGEMAN CA, COHEN TERVAERT JW: -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. Clin Immunol 2002; 103: 154-60.
22. STEGEMAN CA: Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis. Nephrol Dial Transplant 2002; 17: 2077-80.
23. STEGEMAN CA, COHEN TERVAERT JW, SLUITER WJ, MANSON WL, DE JONG PE, KALLENBERG CG: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 12-7.
24. GIRARD T, MAHR A, NOEL LH et al.: Are anti-neutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) 2001; 40(2): 147-51.
25. ARA J, MIRAPEIX E, RODRIGUEZ R, SAURINA A, DARNELL A: Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. Nephrol Dial Transplant 1999; 14: 1667-72.
26. BOOMSMA MM, STEGEMAN CA, VAN DER LEIJ MJ et al.: Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43: 2025-33.
27. SCHLESIER M, KASPAR T, GUTFLEISCH J, WOLFF-VORBECK G, PETER HH: Activated CD4+ and CD8+ T-cell subsets in Wegener's granulomatosis. Rheumatol Int 1995; 14: 213-9.
28. SCHMITT WH, HEESEN C, CSERNOK E, RAUTMANN A, GROSS WL: Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum 1992; 35: 1088-96.
29. SCHMITT WH, CSERNOK E, KOBAYASHI S, KLINKENBORG A, REINHOLD-KELLER E, GROSS WL: Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum 1998; 41: 445-52.
30. STEGEMAN CA, COHEN TERVAERT JW, HUITEMA MG, KALLENBERG CG: Serum markers of T cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol 1993; 91: 415-20.
31. CHRISTENSSON M, PETTERSSON E, SUNDQVIST KG, CHRISTENSSON B: T cell activation in patients with ANCA-associated vasculitis: inefficient immune suppression by therapy. Clin Nephrol 2000; 54: 435-42.
32. POPA ER, STEGEMAN CA, BOS NA, KALLENBERG CG, TERVAERT JW: Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999; 103 (5 Pt. 1): 885-94.
33. OHLSSON S, WIESLANDER J, SEGELMARK M: Low IL-10 levels during remission is associated with a risk of subsequent relapse. Kidney Blood Press Res 2003; 26: 277 (abstract).
34. LAMPRECHT P, BRUHL H, ERDMANN A et al.: Differences in CCR5 expression on peripheral blood CD4+. Clin Immunol 2003; 108: 1-7.
35. RAROK AA, STEGEMAN CA, LIMBURG PC, KALLENBERG CG: Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2002; 13: 2232-8.
36. WITKO-SARSAT V, CRAMER EM, HIEBLOT C et al.: Presence of proteinase 3 in secretory vesicles: evidence of a novel, highly mobilizable intracellular pool distinct from azurophil granules. Blood 1999; 94: 2487-96.
37. SCHREIBER A, BUSJAHN A, LUFT FC, KETTRITZ R: Membrane expression of proteinase 3 is genetically determined. J Am Soc Nephrol 2003; 14: 68-75.
38. WITKO-SARSAT V, LESAVRE P, LOPEZ S et al.: A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol 1999; 10: 1224-33.
39. SCHREIBER A, LUFT FC, KETTRITZ R: Membrane proteinase 3 expression and ANCA-induced neutrophil activation. Kidney Int 2004; 65: 2172-83.
40. VAN ROSSUM AP, RAROK AA, HUITEMA MG, FASSINA G, LIMBURG PC, KALLENBERG CG: Constitutive membrane expression of proteinase 3 (PR3) and neutrophil activation by anti-PR3 antibodies. J Leukoc Biol 2004; 76: 1162-70.
41. VAN DER POL W, VAN DE WINKEL JG: IgG receptor polymorphisms: risk factors for disease. Immunogenetics 1998; 48: 222-32.
42. DIJSTELBLOEM HM, SCHEEPERS RH, OOST WW et al.: Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. Arthritis Rheum 1999; 42: 1823-7.
43. HAGEN EC, STEGEMAN CA, D'AMARO J et al.: Decreased frequency of HLA-DR13DR6 in Wegener's granulomatosis. Kidney Int 1995; 48: 801-5.
44. GENCIK M, BORGMANN S, ZAHN R et al.: Immunogenetic risk factors for anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis. Clin Exp Immunol 1999; 117: 412-7.
45. SPENCER SJ, BURNS A, GASKIN G, PUSEY CD, REES AJ: HLA class II specificities in vasculitis with antibodies to neutrophil cytoplasmic antigens. Kidney Int 1992; 41: 1059-63.
46. STASSEN P, SANDERS JS, LEMS S, COHEN TERVAERT JW, STEGEMAN CA: HLA DR antigens are associated with ANCA-associated vasculitis and relapse during follow up in PR3 but not in MPO-ANCA related vasculitis. Kidney Blood Press Res 2003; 26: 277 (Abstract).
47. REYNOLDS WF, CHANG E, DOUER D, BALL ED, KANDA V: An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 1997; 90: 2730-7.
48. FIEBELER A, BORGMANN S, WOYWODT A, HALLER H, HAUBITZ M: No association of G-463A myeloperoxidase gene polymorphism with MPO-ANCA-associated vasculitis. Nephrol Dial Transplant 2004; 19: 969-71.
49. HUANG D, GISCOMBE R, ZHOU Y, LEFVERT AK: Polymorphisms in CTLA-4 but not tumor necrosis factor-alpha or interleukin 1beta genes are associated with Wegener's granulomatosis. J Rheumatol 2000; 27: 397-401.
50. GISCOMBE R, WANG X, HUANG D, LEFVERT AK: Coding sequence 1 and promoter single nucleotide polymorphisms in the CTLA-4 gene in Wegener's granulomatosis. J Rheumatol 2002; 29: 950-3.
51. BARTFAI Z, GAEDE KI, RUSSELL KA, MURAKOZY G, MULLER-QUERNHEIM J, SPECKS U: Different gender-associated genotype risks of Wegener's granulomatosis and microscopic polyangiitis. Clin Immunol 2003; 109: 330-7.
52. ZHOU Y, GISCOMBE R, HUANG D, LEFVERT AK: Novel genetic association of Wegener's granulomatosis with the interleukin 10 gene. J Rheumatol 2002; 29: 317-20.
53. TURNER DM, WILLIAMS DM, SANKARAN D, LAZARUS M, SINNOTT PJ, HUTCHINSON IV: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8.
54. BORGMANN S, ENDISCH G, HACKER UT, SONG BS, FRICKE H: Proinflammatory genotype of interleukin-1 and inlerleukin-1 receptor antagonist is associated with ESRD in proteinase 3-ANCA vasculitis patients. Am J Kidney Dis 2003; 41: 933-42.
55. SEGELMARK M. ELZOUKI AN, WIESLANDER J, ERIKSSON S: The PiZ gene of alpha 1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis. Kidney Int 1995; 48: 844-50.
56. GENCIK M, MELLER S, BORGMANN S, FRICKE H: Proteinase 3 gene polymorphisms and Wegener's granulomatosis. Kidney Int 2000; 58: 2473-7.
57. CAPIZZI SA, SPECKS U: Does infection play a role in the pathogenesis of pulmonary vasculitis? Semin Respir Infect 2003; 18: 17-22.
58. CHOI HK, LAMPRECHT P, NILES JL, GROSS WL, MERKEL PA: Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum 2000; 43: 226-31.
59. PINCHING AJ, REES AJ, PUSSELL BA, LOCKWOOD CM, MITCHISON RS, PETERS DK: Relapses in Wegener's granulomatosis: the role of infection. Br Med J 1980; 281: 836-8.
60. RAYNAULD JP, BLOCH DA, FRIES JF: Seasonal variation in the onset of Wegener's granulomatosis, polyarteritis nodosa and giant cell arteritis. J Rheumatol 1993; 20: 1524-6.
61. STEGEMAN CA, COHEN TERVAERT JW, DE JONG PE, KALLENBERG CG: Trimethoprimsulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335: 16-20.
62. FAUCI AS, HAYNES BF, KATZ P, WOLFF SM: Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85.
63. POPA ER, STEGEMAN CA, BOS NA, KALLENBERG CG, TERVAERT JW: Staphylococcal superantigens and T cell expansions in Wegener's granulomatosis. Clin Exp Immunol 2003; 132: 496-504.
64. POPA ER, VAN DER MEER B, ARENDS J et al.: Staphylococcal Toxic-Shock-Syndrome-Toxin-1 (TSST-1) is a risk factor for disease relapse in Wegener's granulomatosis. Arthritis Rheum 2002; 46: S207 (abstract).
65. MANDELL BF, CALABRESE LH: Infections and systemic vasculitis. Curr Opin Rheumatol 1998; 10: 51-7.
66. SOMER T, FINEGOLD SM: Vasculitides associated with infections, immunization, and antimicrobial drugs. Clin Infect Dis 1995; 20: 1010-36.
67. CHEN RT, PLESS R, DESTEFANO F: Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun 2001; 16: 309-18.
68. WRAITH DC, GOLDMAN M, LAMBERT PH: Vaccination and autoimmune disease: what is the evidence ? Lancet 2003; 362: 1659-66.
69. DEREMEE RA, MCDONALD TJ, WEILAND LH: Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc 1985; 60: 27-32.
70. ISRAEL HL: Sulfamethoxazole-trimethoprim therapy for Wegener's granulomatosis. Arch Intern Med 1988; 148: 2293-5.
71. REINHOLD-KELLER E, DE GROOT K, RUDERT H, NOLLE B, HELLER M, GROSS WL: Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 1996; 89: 15-23.
72. STEGEMAN CA, TERVAERT JW, KALLENBERG CG: Co-trimoxazole and Wegener's granulomatosis: more than a coincidence? Nephrol Dial Transplant 1997; 12: 652-5.